过去一年中添加的文章,按日期排序
Anti‑epidermal growth factor receptor monoclonal antibody therapy in locally advanced head and neck cancer: A systematic review of phase III clinical trials
LM Nair, R Ravikumar, M Rafi… - Medicine …, 2024 - spandidos-publications.com
7 天前 - … locally advanced head and neck squamous cell carcinoma (… ‑EGFR monoclonal
antibody cetuximab was evaluated in … the effec‑ tiveness of cetuximab plus RT in the treatment …
antibody cetuximab was evaluated in … the effec‑ tiveness of cetuximab plus RT in the treatment …
Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.
Z Hamedi, AY Lo, JD Berkman, ER Alesi - 2024 - ascopubs.org
7 天前 - … or metastatic head and neck squamous cell carcinoma (R/M … cetuximab-based
treatment. Methods: Cohorts were … +CT), and patients treated with cetuximab and platinum+5-FU …
treatment. Methods: Cohorts were … +CT), and patients treated with cetuximab and platinum+5-FU …
… -080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.
SV Ulahannan, TU Marron, H Park, JM Kaczmar… - 2024 - ascopubs.org
7 天前 - … ) in multiple solid tumor cohorts (NCT04485013… head and neck squamous cell
carcinoma (HNSCC) and WT RAS/BRAF, HER2-Neg metastatic colorectal cancer (mCRC) tumors…
carcinoma (HNSCC) and WT RAS/BRAF, HER2-Neg metastatic colorectal cancer (mCRC) tumors…
… 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma …
DM Cognetti, JM Curry, FF Civantos, J Valentino… - 2024 - ascopubs.org
7 天前 - … Here we present updated interim evaluation findings based on a recent data cut
from this study initially presented at the 2023 American Head and Neck Society meeting. …
from this study initially presented at the 2023 American Head and Neck Society meeting. …
Significance of imaging-detected extranodal extension (iENE) in locally advanced head and neck squamous cell carcinoma (LASCCHN) treated with induction …
R Onaga, T Enokida, T Hiyama, N Tanaka, Y Hoshi… - 2024 - ascopubs.org
7 天前 - … , carboplatin, and cetuximab followed by chemoradiotherapy (CRT) from 2013 to
2022 in our hospital. Two radiologists specializing in head and neck cancer blindly annotated …
2022 in our hospital. Two radiologists specializing in head and neck cancer blindly annotated …
Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.
L Sun, J Fayette, S Salas, DS Hong, D Adkins, L Dunn… - 2024 - ascopubs.org
7 天前 - … ≤2 prior lines of systemic therapy (median: 2; range: 1-3), 40 (100%) pts received
prior CPI, 23 (57.5%) pts received prior taxane, and 27 (67.5%) pts received prior cetuximab. …
prior CPI, 23 (57.5%) pts received prior taxane, and 27 (67.5%) pts received prior cetuximab. …
Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma.
7 天前 - … HNSCC pts across different primary tumor sites, with an ORR 56%, including
those with prior taxane exposure. A phase 2 study of FID with cetuximab in pts with HNSCC is …
those with prior taxane exposure. A phase 2 study of FID with cetuximab in pts with HNSCC is …
Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) …
Y Carulla, EM Neidhardt, A Karabajakian… - 2024 - ascopubs.org
7 天前 - … Conclusions: The use of IO less than 3 months before cetuximab lead to better
ORR to cetuximab compared to a delay longer than 3 months. When cetuximab is started early …
ORR to cetuximab compared to a delay longer than 3 months. When cetuximab is started early …
… efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A …
D Ji, Y Sang, X Liu, Y Guo, Y Yang, G Chen, S Dong… - 2024 - ascopubs.org
7 天前 - … cetuximab due to grade 3 rash. Three patients reported fatal AEs, which was
caused by tumor … Conclusions: Camrelizumab combined with cetuximab and cisplatin-based …
caused by tumor … Conclusions: Camrelizumab combined with cetuximab and cisplatin-based …
Prospective monitoring for immunotherapy by liquid biopsy and signal pathway alterations in head and neck cancers.
Y Kano, R Noji, T Naito, S Fujiwara, S Ikeda, T Mori… - 2024 - ascopubs.org
7 天前 - … head and neck squamous cell carcinoma (HNSCC). Comprehensive genome profiling
(CGP) testing including liquid biopsy using cell… the sensitivity to cetuximab-based therapy …
(CGP) testing including liquid biopsy using cell… the sensitivity to cetuximab-based therapy …